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A B S T R A C T
Purpose: Mesial temporal lobe epilepsy (MTLE) is one of the most common forms of epilepsies in adults.
The calcium homeostasis modulator 1 gene (CALHM1) has been considered one of the candidate genes
that play a role in epileptogenesis due to its function in calcium homeostasis and amyloid b (Ab)
regulation. Recently, the association of a single nucleotide polymorphism (rs11191692) of CALHM1 has
been reported to be associated with MTLE in Han Chinese, but independent replication is needed. In the
present study, rs11191692 and rs2986017 of CALHM1 were determined in 512 MTLE patients and 412
control subjects to investigate the possible involvement of CALHM1 in the etiology of MTLE.
Method: Genotyping was determined by polymerase chain reaction-restriction fragment length
polymorphism method. Major statistical analyses were performed by SAS.
Results: No signiﬁcant differences in the genotypic or allelic frequencies of both single-nucleotide
polymorphisms were revealed between subjects with and without MTLE (rs11191692: P = 0.890 and
0.230; rs2986017: P = 0.581 and 0.072). Further stratiﬁcation analysis by gender and age, and analysis of
clinical features in relation to MTLE also yielded negative results.
Conclusion: rs11191692 and rs2986017 of CALHM1 do not contribute substantially to MTLE in Han
Chinese.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Mesial temporal lobe epilepsy (MTLE) is the most common form
of epilepsy and is also responsible for a majority of refractory
epilepsy.1 Genetic factors, together with environmental condi-
tions, contribute to the etiology of sporadic MTLE.
The calcium homeostasis modulator 1 (CALHM1) gene encodes
a glycosylated membrane protein expressed in the brain, and was
ﬁrst reported as a genetic modiﬁer of the age of onset of
Alzheimer’s disease (AD).2 Several lines of evidence indicate that
CALHM1 is a plausible candidate gene for epilepsy. First, CALHM1
has been proved to be a pore-forming ion channel mediated by
both voltage and changes of extracellular Ca2+ concentration, and
experiments from CALHM1 knockout mice suggests the role of* Corresponding author. Tel.: +86 24 62506888.
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http://dx.doi.org/10.1016/j.seizure.2013.11.010CALHM1 in cortical neuronal excitability.3 Second, since MTLE and
AD have shared cognitive and behavioral impairments, similar
underlying mechanisms could account for both diseases, thus it is
conceivable that CALHM1 would be also associated with some
condition of epilepsy.4 Additionally, a recent study in a Chinese
population revealed a positive association between rs11191692
and temporal lobe epilepsy (TLE).5
Prompted by those ﬁndings and the urgency of replication in a
population based study, we performed a replication study of Lv
et al. by investigating rs11191692 and rs2986017 of CALHM1 in
MTLE in a Han Chinese population by a case–control study design.
2. Materials and methods
A total of 512 patients with MTLE (388 males and 124 females,
mean age 31.9 years) and 412 control subjects (244 males and 168
females, mean age 34.2 years) were included in the study by
Xuzhou Hospital from November 2004 to October 2012 (Supple-
mentary Table 1). All subjects were unrelated individuals of Han
Chinese descent, and age and sex ratio were matched betweenvier Ltd. All rights reserved.
Table 1
Genotypic and allelic frequencies of rs2986017 and rs11191692 of CALHM1 in MTLE patients and control subjects.
SNP Genotype/allele MTLE Controls Crude Additive Dominant Recessive
n(%) n(%) P P OR(95% CI) P OR(95% CI) P OR(95% CI)
rs11191692 AA 47(9.18) 35(8.50) 0.890 0.632 1.05(0.85–1.29) 0.679 1.06(0.91–1.38) 0.716 1.09(0.67–1.77)
AG 216(42.19) 171(41.50)
GG 249(48.63) 206(50.00)
A 310(30.27) 241(29.25) 0.230
G 714(69.73) 583(70.75)
rs2986017 AA 4(0.78) 2(0.49) 0.198 0.072 1.37(0.96–1.96) 0.074* 1.39(0.95–2.05) 0.697 1.61(0.25–17.92)
AG 85(16.60) 52(12.62)
GG 423(82.62) 358(86.89)
A 93(9.08) 56(6.80) 0.072
G 931(90.92) 768(93.20)
* Two-tailed P value of Fisher’s exact test.
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unrelated group and did not have a history of seizures, including
febrile convulsions; related family histories; or inherited central
nerve system diseases. MTLE patients were diagnosed according to
the ‘‘Classiﬁcation of Epilepsies and Epileptic Syndromes’’ pro-
posed by the Commission on Classiﬁcation and Terminology of the
International League Against Epilepsy.6 MTLE was diagnosed when
seizure semiology implied mesial temporal lobe origin. Video
electroencephalogram with dominant temporal ictal or interictal
discharge spikes and magnetic resonance imaging (MRI) showing a
sign of hippocampus sclerosis (HS) also supported the diagnosis.
MTLE was ruled out when: (1) cerebral tumor, vascular lesion or
malformation, and epilepsy-related focal necrosis were found on
neurological examination or MRI; (2) causal relationship of head
trauma, birth injures, and inﬂammation with epilepsy was
unequivocal; (3) further evidence was found to support other types
of epilepsy and epilepsy syndromes apart from MTLE; (4) psychiatric
disorders, other neurological inherited diseases, or obvious mental
retardation was present; or (5) obvious autosomal-dominant
inherited epilepsy was revealed in 3 ﬁrst-degree relatives.
Informed consent for the anonymous use of their DNA for the
purposes of this study was obtained from all enrolled subjects. The
study was performed with the approval of the ethics committee in
the Afﬁliated Hospital of Xuzhou Medical College.
The genomic DNA was extracted from the peripheral blood by a
salting-out protocol. rs11191692 and rs2986017 were genotyped
by restriction fragment length polymorphisms (RFLPs) followed by
polymerase chain reaction (PCR). The 231- and 248-bp regions
harboring rs11191692 and rs2986017 of CALHM1, respectively,
were ampliﬁed by a standard PCR protocol with primers of
rs11191692 (forward 50-AAGGATGGAATCATGCCAAG-30; reverse
50-CATAGTAGGCACCCAGCACA-30) and rs2986017(forward 50-
AACATGTAGCGCAACACAGC-30 and reverse 50-TCCTTCATGAATGG-
CATCTG-30). Detailed PCR conditions are available upon request.
An aliquot (8–10 ml) of the PCR products was digested for 3 h by
10 units/sample of AciI (for genotyping rs11191692) or BseYI (for
genotyping rs2986017) at 37 8C. Enzymes were from the China
Branch of New England Biolabs Inc. The G allele of rs11191692
yielded 70-, and 161-bp fragments, while the A allele ofTable 2
Clinical features in MTLE patients in relation to genotypes of rs2986017 and rs111916
SNP Genotypes Age at onset 
Years, median(min–max) P 
rs11191692 AA 13(4–27) 
AG 21(14–37) 
GG 17(14–42) 0.21
rs2986017 AA + AG 19(4–37) 
GG 18(12–42) 0.76rs11191692 yielded a 231-bp fragment; the A allele of
rs2986017 yielded 40- and 208-bp fragments and the G allele
remained the 248-bp fragment. Those restriction fragments were
resolved by gel electrophoresis and were visualized under
ultraviolet light. Twenty samples were randomly selected to
conﬁrm the genotypes of PCR–RFLP by sequencing.
The Hardy–Weinberg equilibrium was assessed in the controls
by x2 test. Differences in the frequencies of genotypes or alleles
between the patient and control groups were tested in 2  3 or
2  2 contingency tables using EPI Info. Haplotype analysis was
performed using SHEsis at http://analysis.bio-x.cn.7 Kruskal–
Wallis test or t-test was performed to test distributions of
quantitative traits. These tests were performed using SAS 9.1.2
(SAS Institute, Inc., Cary, NC). Power analysis was performed using
Power and Sample Size Calculations.8 Two-sided P-values below
0.05 were considered statistically signiﬁcant.
3. Results
The baseline characteristics of our study cohort are shown in
Supplementary Table 1. There was no signiﬁcant difference of age
and male/female ratio between MTLE patients and control
subjects. Even we have excluded patients who had a deﬁnite
causal relationship of head trauma, birth injures, and inﬂammation
with epilepsy, a small fraction (3.9%) of our patients reported an
antecedent event such as brain trauma or encephalitis but no
evidence suggested those were causal events.
Genotypic distributions of rs11191692 and rs2986017 in
control subjects were in Hardy–Weinberg equilibrium. No
statistical signiﬁcance was observed for both allelic and genotypic
analysis of both SNPs (rs11191692: P = 0.230 and P = 0.890,
respectively; rs2986017: P = 0.072 and P = 0.198, respectively,
Table 1). Consistent with the single SNP tests, no differences were
found between the three haplotypes consisting of rs11191692 and
rs2986017 (Supplementary Table 2). Given the low occurrence of
the AA genotype of rs2986017 in our samples, MTLE patients
carrying at least one copy of A allele were grouped, and compared
to the GG carriers with respect to age at onset, aura % and HS % in92.
Aura Hippocampal sclerosis
n(%) P n(%) P
39(10.89) 17(8.99)
143(39.94) 84(44.44)
0 176(49.16) 0.070 87(46.03) 0.676
64(17.88) 38(20.11)
2 294(82.12) 0.653 151(79.89) 0.214
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found for rs11191692 and rs2986017.
4. Discussion
Our negative result of rs2986017 is in agreement with Dr. Lv
et al.’s study. Accumulative evidences support that rs2986017 is a
functional SNP. First, rs2986017 produces an amino-acid substi-
tution at codon 86 (Pro/Leu). Second, in vitro studies have shown
that it causes attenuated CALHM1 function resulting in a reduced
calcium permeability and low cytoplasmic calcium levels.2 Third, it
is signiﬁcantly associated with cerebrospinal ﬂuid Ab levels in
human samples.9 Lastly, human genetic studies have repeatedly
demonstrated the association between rs2986017 and AD.2,10
Since no experimental evidence so far supports the biological
validity of rs11191692, the negative results of rs2986017 may
indicate the non-relevance of the CALHM1 locus in MTLE in Han
Chinese.
rs1119162 locates in the 30 untranslated region of CALHM1 but
does not directly affect the known miRNAs binding sites (see
Supplementary Table 3 and Supplementary Figure).The original
odds ratio (OR) of the rs11191692 A allele was 1.42,5 and always
the true effect could be even smaller.11 Our sample size is able to
provide almost 70% power to replicate this allelic association (OR
of 1.42) given 30% of the allelic frequency in controls and a Type I
error probability of 0.05. If the OR is 1.2, the power of our study will
be dropped to 25%, so it is possible that the initial positive ﬁnding
revealed a true association, but one that is less strong in our
samples. If this is the case, then the underpowered sample size
should account for the replication failure. Undetected population
stratiﬁcation could also have resulted in non-replication. It is
worth noting that our samples are from south China while the
original reports were predominantly from the north. The frequency
of the rs11191692 A allele in our control population was 29.25%,
which is very close to the 29.9% frequency in the Chinese Han data
from the Hapmap Project (http://hapmap.ncbi.nlm.nih.gov/), and
is higher than that in the original report (around 26%). Indeed, a
one-dimensional ‘‘north–south’’ population structure has been
revealed in over 6000 Han Chinese samples from various provinces
of China.12 So we cannot exclude the possibility that the difference
in the CALHM1 haplotypic structure between Northern Chinese and
Southern Chinese resulted in nonreplication.In summary, the present study provides evidence that
rs2986017 and rs11191692 in CALHM1 are not associated with
MTLE in the Chinese population.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.seizure.2013.
11.010.
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